PDS Biotechnology Corp
About PDS Biotechnology Corp
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$34.5M
- Total assets
- $30.5M
- Market cap
- $56.9M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $31.5M
- Operating income
- -$31.5M
- Income tax
- -$1.2M
- Net income
- -$34.5M
- EPS (basic)
- $-0.74
- EPS (diluted)
- $-0.74
Balance sheet
- Total assets
- $30.5M
- Current assets
- $28.3M
- Total liabilities
- $21.2M
- Current liabilities
- $9.5M
- Shareholders’ equity
- $9.3M
Cash flow
- Operating cash flow
- -$27.8M
- Investing cash flow
- $15.0M
- Financing cash flow
- $12.8M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $56.9M
- EPS (diluted)
- $-0.74
- Shares outstanding
- 53.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 1, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $34.5M.
- Trading 41% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review PDS Biotechnology Corp.
Write a review
News about PDS Biotechnology Corp
News & sentiment via Polygon.io
